Tag: GlobeNewswire

• 100% clinical success and no device-related adverse events in 20 First-in-Human Percutaneous Coronary Intervention procedures with next-generation robotic system
• Robocath system demonstrates ability to efficiently and effectively support the full range of coronary interventions including in complex coronary artery disease patients
• Principal investigator, Dr. Nejjari, shared the findings during the “Innovations in Robotics for Transcatheter Heart Interventions” session at TCT on November 1, 2026

ST. LOUIS and ROUEN, France, Nov. 02, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the findings from the first-in-human clinical results for Robocath’s next-generation robotic system during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. The findings support a favorable performance profile for the system, with 100% clinical success rate and no device-related complications.

The study was conducted by Dr. Mohammed Nejjari and Dr. Franck Digne, Interventional Cardiologists at Centre Cardiologique du Nord (CCN) in Saint-Denis, France. This prospective pilot clinical study enrolled twenty patients undergoing PCI for coronary artery disease. Key findings from the study include:

• 100% clinical success and 95% technical success: All 20 patients met the study’s clinical success criteria of minimal residual stenosis post PCI. In all but one procedure the physician was able to complete the procedure entirely robotically without conversion to manual.
• No device-related adverse events: Clean safety profile with no intra-procedural vascular complications, major adverse events, or device related adverse events through 30-day follow-up
• No physician radiation exposure: Operating physicians performed the procedures entirely protected from fluoroscopy radiation, supporting the system’s potential to reduce occupational risk in interventional cardiology.
• Performance across lesion complexity: The study included A/B1, B2, and C-type lesions, representing three levels of procedural complexity, including in complex coronary disease in tortuous distal vasculature.

Dr. Nejjari discussed these findings during the November 1, 2026 scientific session “Innovations in Robotics for Transcatheter Heart Interventions” that took place at TCT. A manuscript documenting these findings has been submitted for publication and is under review.

“These initial findings mark an important milestone in the advance of robotic technology in interventional cardiology,” said Dr. Nejjari. “The results are very encouraging, particularly the clinical success and safety observed across the patient cohort including in complex PCI. We are excited for the potential of this robotic innovation to improve care for patients and benefit physician safety and workflow.

Robocath, a subsidiary of Stereotaxis, is a technology leader in pioneering advanced robotic innovations for interventional cardiology and neurointerventions. Robocath’s next-generation system builds on the clinical and technological experience of the first-generation R-One system, now used in centers worldwide. It adds advanced capabilities such as multi-device handling of up to five interventional devices simultaneously to support increasingly complex interventional procedures.

“These first-in-human results support our confidence in our innovation strategy and reflect our commitment to advancing differentiated robotic technologies across endovascular interventions,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to building on these initial findings, progressing Robocath’s technology towards regulatory submissions, and delivering this promising technology to interventional physicians and patients suffering from coronary disease and stroke.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Brief Details the Evidence and Law Supporting the Jury’s Findings on Inducement, Contributory Infringement and Damages; Post-Judgment Interest Continues to Accrue During the Appeal

CORSICANA, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that it has filed its appellee brief with the U.S. Court of Appeals for the Federal Circuit in response to the appeal filed by the CERT defendants challenging the approximately $78 million final judgment entered in favor of Birchtech by the U.S. District Court for the District of Delaware.

Birchtech filed the brief on October 22, 2026, in Birchtech Corp. v. Arthur J. Gallagher & Co., et al., Federal Circuit Case No. 2026-1403, on appeal from District of Delaware Case No. 1:19-cv-01334-CJB. The brief asks the Federal Circuit to affirm the jury’s verdict and the District Court’s final judgment in full.

The patent litigation, which involves Birchtech’s patented SEA^® (Sorbent Enhancement Additive) mercury emissions control technology for coal-fired power plants, was originally filed in July 2019 against 43 defendants. By the March 2024 jury trial, the case had narrowed to the remaining CERT defendants following settlements and license agreements with other defendants. A federal jury in the District of Delaware returned a unanimous $57 million verdict against the CERT defendants, finding them liable for willful infringement, along with inducing and contributory infringement. In December 2025, the Court increased the final judgment amount to $78.4 million awarded to Birchtech, inclusive of pre-judgment interest, with post-judgment interest continuing to accrue daily.

The brief responds to each of CERT’s challenges to the verdict and judgment, including those concerning liability, the jury instructions and damages. In doing so, it cites and quotes the District Court’s pretrial and post-trial opinions, issued before entry of final judgment, in which the Court reaffirmed the legal standards applied at trial and rejected many of the same arguments CERT now raises on appeal.

The appeal does not suspend the accrual of interest. Post-judgment interest on the judgment continues to accrue until it is paid.

Management Commentary

“Our response is absolute and clear in upholding the unanimous jury verdict and the $78 million final judgment the District Court entered on that verdict,” said Richard MacPherson, President and Chief Executive Officer of Birchtech. “We will continue to defend our SEA^® patents, pursue full collection of the judgment with interest, and keep turning former users of our technology into licensed, long-term customers.”

Background on 2019 Patent Litigation

• July 2019: Birchtech (then Midwest Energy Emissions Corp.) files its patent infringement lawsuit against 43 defendants in the U.S. District Court for the District of Delaware. Read the release.
• March 2024: A federal jury returns a unanimous $57 million verdict against the CERT defendants, finding willful infringement, along with inducing and contributory infringement. Read the release.
• December 2025: The Court increases the final judgment amount to $78.4 million, inclusive of pre-judgment interest, with post-judgment interest continuing to accrue daily. Read the release.
• January 28, 2026: CERT files its notice of appeal to the Federal Circuit.
• February 2, 2026: Birchtech formally requests payment of the full judgment. Read the release.
• June 3, 2026: Every inter partes review petition challenging Birchtech’s SEA^® patents has been dismissed, removed prior to institution, or resolved. Read the release.
• October 22, 2026: Birchtech files its response brief with the Federal Circuit. Read the filing.

Since launching its patent enforcement program in 2019, Birchtech has received approximately $37.0 million in license fees and settlements from utilities.

About Birchtech Corp.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a leader in specialty activated carbon technologies delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA® sorbent technologies for mercury emissions capture for the coal-fired utility sector and SEA disruptive water purification technologies with a specialization on removing contaminants, including ‘forever chemicals’ such as PFAS, from potable water and industrial wastewater. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to a novel approach in water purification. To learn more, please visit www.birchtech.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the enforcement and collection of the Company’s judgment, the appellate process, and its outcome, the timing, amount or likelihood of any recovery under the judgment, and the accrual and potential recovery of post-judgment interest. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Birchtech does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in Birchtech’s periodic filings with the Securities and Exchange Commission or Canadian securities regulators.

Investor Relations Contact

Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BCHT@mzgroup.us
www.mzgroup.us

Latest step in newcleo’s vertical integration strategy secures weighing equipment supply for its US and European MOX fuel manufacturing programs

LONDON and PARIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — newcleo plc (“newcleo” or the “Company”) (Nasdaq: NWCL), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced that it has completed its previously announced acquisition of Bonifait Pesage, a French maker of nuclear-grade scales and precision weighing equipment that serves high profile customers across the French nuclear sector.

The deal extends the vertical integration approach newcleo has pursued since 2023, when it acquired Fucina, SRS and Rütschi. The acquisition of Bonifait Pesage brings another specialist supplier under the newcleo umbrella ahead of development of the Company’s planned mixed-oxide (MOX) fuel manufacturing facilities in the United States and Europe, where nuclear-grade weighing equipment will support the tracking and control of nuclear materials. Through the acquisition of Bonifait Pesage, newcleo gains preferred access to specialized precision weighing equipment, lowers its supply-chain exposure and can tailor equipment to its own requirements.

“Bonifait Pesage adds a further building block to the vertically integrated supply chain we have assembled to produce MOX fuel for our lead-cooled fast reactors,” said Stefano Buono, CEO and Co-Founder of newcleo. “Having their expertise and technologies inside newcleo will allow us to build our MOX fuel facilities on a supply chain we know and can rely on. We welcome the Bonifait Pesage team and will continue supporting their growth as a supplier to the wider nuclear industry.”

“Our team now joins a group that is building across the nuclear fuel cycle,” said Laurent Bonifait, Founder of Bonifait Pesage. “Operating as part of the newcleo team gives us a platform to grow leveraging the global growth of the nuclear industry, while we continue to serve the historical customers who rely on us.”

Bonifait Pesage, founded in 1954 and based in southern France, manufactures, installs, calibrates and services weighing equipment and provides technical support. Since 2017 it has been certified to maintain and verify weighing systems in ionizing-radiation environments, and its specialist staff are qualified to work in areas where radiation exposure may occur. The company reported revenue of approximately €2.1 million in 2025. The transaction valued Bonifait Pesage at an equity value of €1.8 million, with purchase consideration comprising a combination of cash and newcleo shares.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit www.newcleo.com

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.

For media Inquiries
media@newcleo.com

For investors
newcleo@icrinc.com

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).

Trading day	No. of shares	Average price	Amount DKK
Accumulated until 23 October 2026	557,541	722.93	403,065,580
Monday, 26 October 2026	750	847.00	635,250
Tuesday, 27 October 2026	830	831.08	689,800
Wednesday, 28 October 2026	830	834.00	692,220
Thursday, 29 October 2026	830	835.92	693,814
Friday, 30 October 2026	830	829.00	688,070
In the period 26 October 2026 – 30 October 2026	4,070	835.17	3,399,154
Accumulated until 30 October 2026	561,611	723.75	406,464,734
Following the above transactions, Schouw & Co. holds a total of 2,859,404 treasury shares corresponding to 11.44% of the total share capital of 25,000,000 shares.

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22

Attachments

• 2026-11-02 FBM26-65 SBB-w44 ENG
• SBB2026 Week 44

WOODBURY, NY, Nov. 02, 2026 (GLOBE NEWSWIRE) — Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its third quarter 2026 financial results on Thursday, November 5, 2026. Research Frontiers will also host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2026 to discuss its third quarter 2026 financial and operating results, as well as recent developments.

• Who: Joseph M. Harary, President & CEO
• Date/Time: Thursday, November 5, 2026, 4:30 PM ET
• Dial-in Information: 1-888-334-5785
• Conference Link: https://join.broaddata.com/?id=research-frontiers
• Questions: Email to Questions@SmartGlass.com
• Replay: Available on Friday, November 6, 2026 for 90 days at https://smartglass-ir.com/

About Research Frontiers

Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc.

CONTACT
Joseph M. Harary
President and CEO
Research Frontiers Inc.
 +1-516-364-1902
Info@SmartGlass.com

MIDLAND, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Big Digital Energy, Inc. (“We,” “Big Digital” or the “Company”) (Nasdaq: “BGDE”), a developer and operator of next-generation digital infrastructure, today announced that Executive Chairman Josh Kilgore and Chief Executive Officer Phil Stanley will participate in the Cantor Crypto and AI Infrastructure Conference, taking place November 10–12, 2026, in Miami, Florida. Mr. Kilgore will also participate in a panel discussion on Thursday, November 12, at 11:20 a.m. ET. Interested investors should contact their Cantor representatives to schedule a meeting during the conference.

Cantor Crypto and AI Infrastructure Conference

• Date: November 10-12, 2026
• Location: Miami, FL
• Panel Discussion with Executive Chairman Josh Kilgore: November 12, 2026, at 11:20 a.m. ET

About Big Digital Energy, Inc.

Big Digital Energy, Inc. (Nasdaq: “BGDE”) is a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms. The Company provides services spanning artificial intelligence (“AI”), high-performance computing (“HPC”), digital assets (including Bitcoin mining), and other intensive compute applications. The Company delivers both self-mining operations and colocation/hosting for enterprise customers, with a vertically integrated infrastructure model built for scalability and efficiency.

A core part of the Company’s strategy is identifying and advancing sites positioned to support high-performance compute with the infrastructure required for long-term deployment. With approximately 169 megawatts of energized capacity and additional capacity under development, the Company is positioning itself as a competitive provider of digital infrastructure solutions to support the demand for AI data centers.

CONTACT

Investor Relations: IR@bigdigital.energy
Partnerships: Partnerships@bigdigital.energy
Media and Press: mediarelations@bigdigital.energy
Website: www.bigdigital.energy

MOA establishes framework to assess potential deployment of Roze AI’s fire forecasting system across seven planned data center developments in South Korea

SEONGNAM, South Korea, Nov. 02, 2026 (GLOBE NEWSWIRE) — Roze AI Inc. (Nasdaq: RZAI) (“Roze AI” or the “Company”) today announced that its wholly owned Korean operating subsidiary, Roze AI Korea Co., Ltd., signed a Memorandum of Agreement (“MOA”) with BKB Energy Co., Ltd. on October 20, 2026, to evaluate the technical suitability and feasibility of integrating Roze AI’s proprietary AI fire forecasting system into BKB Energy’s planned AI data center development projects.

Young Jin Cho, Chief Executive Officer of Roze AI, stated, “We see BKB Energy’s planned development of AI data centers across seven locations in South Korea as a significant opportunity to demonstrate the value of our AI fire forecasting system. This MOA provides a framework for working with the relevant parties to determine the scope of technical implementation, design requirements, and commercial terms necessary for a definitive agreement.”

Under the MOA, the parties will evaluate how Roze AI Korea’s technologies may be applied to the planned facilities and incorporated into project plans and designs. Discussions will cover technical specifications, installation integration, and operational and maintenance arrangements, with the objective of determining whether the system should be deployed and how it may be adapted to the requirements of each facility. Requirements relating to legally mandated fire protection systems will be addressed separately in accordance with applicable laws and regulations.

According to BKB Energy, its AI data center development projects identified in the MOA are planned to proceed sequentially. The currently planned project sites are as follows:

1. Hannam University Defense AX Center, Daejeon – 240 MW (Phase 1: 40 MW)
2. Yeongwol, Gangwon Province (EMP-protected facility) – 260 MW
3. Samcheok, Gangwon Province – 800 MW
4. Okgye, Gangwon Province – 200 MW
5. Pocheon, Gyeonggi Province – 120 MW
6. Pyeongtaek, Gyeonggi Province – 200 MW
7. Hongseong, South Chungcheong Province – 80 MW

The MOA establishes a non-binding framework for cooperation between the parties. If definitive agreements are subsequently executed, the final scope, pricing, and commercial terms for the AI fire forecasting system and associated components to be supplied by Roze AI Korea—including sensors, monitoring, alerting, and software—will be determined based on project feasibility assessments, the authority to enter into contracts, required approvals, and the execution of separate definitive agreements. The MOA does not constitute a binding purchase order, revenue guarantee or capital commitment by Roze AI.

Under the MOA, the parties have established an initial target period of 60 days from the execution date for technical review and discussions of commercial terms. This period is not a deadline for executing a definitive agreement and may be adjusted in writing depending on the progress of discussions. The MOA will remain in effect until October 20, 2027, unless terminated earlier or extended in writing.

About Roze AI Inc.

Roze AI is a Canadian Physical AI technology company operating through its wholly owned subsidiary, Roze AI Korea Co., Ltd., in Seongnam, South Korea.

The Company’s Disaster AI Platform (DAP) analyzes sensor and facility data using AI and digital twin technology to generate a Fire Risk Index that supports fire risk assessment, monitoring and early warning.

Through Roze AI Korea Co., Ltd., the Company develops and provides Fire 4Cast, Disaster AI Platform (DAP) and other solutions for buildings, facilities and urban infrastructure.

For more information, please visit www.rozeai.com.

Investor Relations / Media Relations

Roze AI Inc.
Email: ir@rozeai.com

Investor Relations – North America

Jack Perkins
KCSA Strategic Communications
Email: rozeai@kcsa.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements under applicable U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. These include the potential business scope under the MOA; its possible progression to a definitive agreement; and technology application. These statements reflect current expectations, estimates and assumptions and are subject to risks and uncertainties.

Actual results may differ materially due to feasibility findings; contracting authority and third-party decisions; permits and approvals; project financing; design, scope, price or schedule changes; failure to enter definitive agreements; termination, postponement or cancellation; technology requirements; customer performance and revenue recognition; regulatory and market conditions; and risks described in the Company’s SEC filings. Readers should not place undue reliance on these statements, which speak only as of this release. The Company undertakes no obligation to update them except as required by applicable law.

PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) — L.B. Foster Company (NASDAQ: FSTR), a global technology solutions provider of products and services for the Rail and Infrastructure markets, announced today that its Board of Directors has approved certain changes among its executive officers effective November 1, 2026 (the Effective Date).

Ms. Sara Rolli currently serves as the Company’s Senior Vice President – Operational Administration and is appointed Senior Vice President – Steel Products and Operational Excellence on the Effective Date, and will continue to report to Bill Thalman, Executive Vice President and Chief Operating Officer. In addition to her current responsibilities overseeing the Company’s Quality, EHS and Continuous Improvement functions, Ms. Rolli will now have operational oversight of the Steel Products business unit within the Company’s Infrastructure segment.  Ms. Rolli, age 45, has served as SVP – Operational Administration since 2025, served as VP – Operational Administration from 2023 – 2025, and served as the Company’s Director of Quality from 2019 – 2023. She was also Senior Quality Manager from 2015 – 2017 and Site Quality Manager from 2013 – 2015. Prior to joining the Company, Ms. Rolli was employed by Kennametal, Inc. and Praxair. Ms. Rolli holds Bachelor of Science and Master of Arts degrees from Waynesburg University.

In connection with Ms. Rolli’s change in responsibilities, Mr. Robert (Bob) Ness, currently serving as Senior Vice President – Infrastructure segment, is appointed Senior Vice President – Precast Concrete Products on the Effective Date, also continuing to report to Mr. Thalman. He will cease to serve as SVP – Infrastructure on the Effective Date and will lead the Company’s Precast Concrete Products business unit.

Mr. Thalman commented, “We’re pleased to recognize Sara with this important change to her responsibilities. She’s been a valued leader in our organization for over a decade, establishing rigor and sustainability in our Quality, Lean and EHS business processes. This additional assignment overseeing the Steel Products business unit is the next step in her career progression and adds to our operational bench strength. The change also provides Bob with additional bandwidth to focus on our growth initiatives for the Precast Concrete business unit, which is a critical growth platform within our strategic playbook. I congratulate Sara on this well-deserved recognition and look forward to the contributions both Sara and Bob will make in the future.”

Forward-Looking Statements

This release may contain “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements provide management’s current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements. Forward-looking statements in this earnings release are based on management’s current expectations and assumptions about future events that involve inherent risks and uncertainties and may concern, among other things, the Company’s expectations relating to our strategy, goals, projections, valuations and impairments, and plans regarding our financial position, liquidity, capital resources, results of operations and decisions regarding our strategic growth initiatives, market position, and product development. While the Company considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. The Company cautions readers that various factors could cause the actual results of the Company to differ materially from those indicated by forward-looking statements. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Among the factors that could cause the actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to: adverse economic conditions in the markets we serve, including recession, the volatility in the prices for oil and gas, tariffs, duties or trade wars, inflation, rising labor costs, project delays, and budget shortfalls, or otherwise; the disruption of government funding programs as a result of potential periodic government shutdowns; volatility in the global capital markets, including interest rate fluctuations, which could adversely affect our ability to access the capital markets on terms that are favorable to us; restrictions on our ability to draw on our credit agreement, including as a result of any future inability to comply with restrictive covenants contained therein; a decrease in freight or transit rail traffic; environmental matters and the impact of environmental regulations, including any costs associated with any remediation and monitoring of such matters; the risk of doing business in international markets, including compliance with anti-corruption and bribery laws, foreign currency fluctuations and inflation, global shipping disruptions, the imposition of increased or new tariffs, and trade restrictions or embargoes, or uncertainties relating to the imposition and enforcement of tariffs; our ability to timely effectuate our strategy, including cost reduction initiatives, and our ability to effectively integrate acquired businesses or to divest businesses, and to realize anticipated synergies and benefits; costs of and impacts associated with shareholder activism; the timeliness, cost, and availability of materials from our major suppliers, as well as the impact on our access to supplies of customer preferences as to the origin of such supplies, such as customers’ concerns about conflict minerals; labor disputes; emerging technologies, including those related to or arising from artificial intelligence, and resultant risks to our business and operations; cybersecurity risks such as data security breaches, malware, ransomware, “hacking,” and identity theft, either with respect to our systems or those of third parties on whom we rely, which could disrupt our business and may result in misuse or misappropriation of confidential or proprietary information, and could result in the disruption or damage to our systems, increased costs and losses, or an adverse effect to our reputation, business or financial condition; the continuing effectiveness of our ongoing implementation of an enterprise resource planning system; changes in current accounting estimates and their ultimate outcomes; the adequacy of internal and external sources of funds to meet financing needs, including our ability to negotiate any additional necessary amendments to our credit agreement or the terms of any new credit agreement, the Company’s ability to manage its working capital requirements and indebtedness; domestic and international taxes, including estimates that may impact taxes; domestic and foreign government regulations, including tariffs; our ability to maintain effective internal controls over financial reporting and disclosure controls and procedures; any change in policy or other change due to the results of the UK’s parliamentary elections and the U.S. presidential and congressional elections that could affect UK or US business conditions; other geopolitical conditions, including the ongoing conflicts between Russia and Ukraine, conflicts in the Middle East, and increasing tensions between China and Taiwan; a lack of, freezing of, or delay in state or federal funding for infrastructure projects; an increase in manufacturing or material costs, including volatility in steel prices, oil prices, and wage inflation; the loss of future revenues from current customers; any future global health crises, and the related social, regulatory, and economic impacts and the response thereto by the Company, our employees, our customers, and national, state, or local governments, including any governmental travel restrictions; and risks inherent in litigation and the outcome of litigation and product warranty claims. Should one or more of these risks or uncertainties materialize, or should the assumptions underlying the forward-looking statements prove incorrect, actual outcomes could vary materially from those indicated. Significant risks and uncertainties that may affect the operations, performance, and results of the Company’s business and forward-looking statements include, but are not limited to, those set forth under Item 1A, “Risk Factors,” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, or as updated and/or amended by our other current or periodic filings with the Securities and Exchange Commission.

The forward-looking statements in this release are made as of the date of this release and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by the federal securities laws.

Marketing and Communications:

Meredith Faust
412-928-3400, and follow the prompts
lbfmarketing@lbfoster.com

L.B. Foster Company
415 Holiday Drive
Suite 100
Pittsburgh, PA 15220

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:

• Guggenheim 3^rd Annual Healthcare Innovation Conference on Monday, November 9^th at 10:30 a.m. ET
• Stifel 2026 Healthcare Conference on Thursday, November 12^th at 2:00 p.m. ET
• UBS Global Biopharma Conference on Tuesday, November 17^th at 3:40 a.m. ET / 8:40 a.m. GMT
• Jefferies London Global Healthcare Conference on Wednesday, November 18^th at 6:30 a.m. ET / 11:30 a.m. GMT

Disc management will be participating in investor meetings during the above conferences, as well as during the Truist BioPharma Symposium in New York on Thursday, November 12.

Live webcasts of the fireside chats will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Kevin Lui
Precision AQ
kevin.lui@precisionaq.com

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
Tim.Palmer@bicara.com